|
Characterization of Arrhythmia Substrate to Ablate Persistent Atrial Fibrillation
RECRUITINGN/ASponsored by Ottawa Heart Institute Research Corporation
Actively Recruiting
PhaseN/A
SponsorOttawa Heart Institute Research Corporation
Started2018-08-24
Est. completion2024-12
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT03347227
Summary
A multicentre, parallel group, two arm, single-blinded randomized clinical trial, assessing the efficacy of a patient-tailored catheter ablation (CA) strategy guided by atrial scar mapping in addition to pulmonary vein isolation (PVI) when compared to PVI alone in patients with persistent atrial fibrillation (AF).
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: 1. Age ≥18 years ; 2. Subjects with symptomatic persistent AF AND clinically indicated catheter ablation for AF 3. At least one episode of AF that is sustained beyond 3 months in duration ; documented on 12-lead ECG, Holter monitor, loop monitor or trans-telephonic monitor (TTM) within 36 months of enrollment in the study; 4. Modified DR-FLASH score \>=4 4\. Subjects must be able to provide informed consent. Exclusion Criteria: 1. History of previous catheter ablation for AF or left atrial flutter; 2. History of previous surgical ablation for AF; 3. Known intracardiac thrombus; 4. Contraindication to systemic oral anticoagulation therapy; 5. Reversible causes of AF; 6. Hypertrophic cardiomyopathy; 7. Severe valvular disease (mitral/aortic stenosis or regurgitation); 8. Subjects that are pregnant or breastfeeding; 9. Comorbid condition with life expectancy \< 1 year
Conditions2
Atrial FibrillationHeart Disease
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorOttawa Heart Institute Research Corporation
Started2018-08-24
Est. completion2024-12
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT03347227